Our portfolio company Targovax ASA has announced its fourth quarter and full year 2016 results.
Radforsk porfolio company Photocure reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016.
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis. Large privately owned investment companies joining the Company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene […]
Our portfolio company PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”. The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech’s photochemical internalization (PCI) technology can be used […]
The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.
The grant will be used to further development of the existing preclinical research collaboration of the two companies.
*From the laboratory to rocket on the stock exchange – he turns medicine to gold.*
The Private Placement was significantly oversubscribed by both existing shareholders and new investors.
PCI Biotech has received clearance by the United States Food and Drug Administration (FDA) to include patients in the US.